Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 22 - Sexually transmitted diseases

from Section 3 - Gynecological infectious disease

References

1. EngTR, ButlerWT (eds.). The Hidden Epidemic: Confronting Sexually Transmited Diseases. Committee on Prevention and Control of Sexually Transmitted Diseases. Washington, DC: Institute of Medicine National Academy Press, 1997.
2. CatesW, American Social Health Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis 1999;26(Suppl):S2–S7.
3. WeinstockH, BermanS, CatesW Jr. Sexually transmitted diseases among American youth: Incidence and prevealence estimates, 2000. Perspect Sex Reprod Health 2004;36:1–10.
4. ChessonHW, BlandfordJM, GiftTL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:1–20.
5. World Health Organization. Sexually Transmitted Infections. Geneva: World Health Organization, 2013 (http://www.who.int/mediacentre/factsheets/fs110/en/, accessed 26 February 2014).
6. Centers for Disease Control and Prevention. Summary of notifiable diseases: United States 2009. MMWR 2011;58:1–117.
7. BermanSM, HeinK. Adolescents and sexually transmitted diseases. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 129–142.
8. CatesW Jr. Epidemiology and control of sexually transmitted diseases: strategic evaluation. Infect Dis Clin North Am 1987;1:1–23.
9. OverM, PiotP. HIV infection and sexually transmitted disease. In JamisonDT, MosleyWH, MeashamAR, BobadillaJL (eds.) Disease Control Priorities in Developing Countries. New York: Oxford University Press, 1993, pp. 455–527.
10. MeyerTF. Pathogenic Neisseriae: complexity of pathogen–host cell interplay. Clin Infect Dis 1999;28:433–441.
11. HookEW, HandsfieldHH. Gonococcal infections in adults. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 451–466.
12. SweetRL, GibbsRS. Infectious Diseases of the Female Genital Tract, Ch. 5: Sexually transmitted diseases. Philadelphia, PA: Lippincott Williams & Wilkins, 2008. pp. 51–79.
13. BarlowD, PhillipsI. Gonorrhea in women: diagnostic clinical and laboratory aspects. Lancet 1978;i:761.
14. SweetRL, GibbsRS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia, PA: Lippincott, Williams & Wilkins, 2004.
15. SuleimanSA, GrimesEM, JonesHS. Disseminated gonococcal infections. Obstet Gynecol 1983;61:48–51.
16. HolmesKK, CountsGW, BeatyHN. Disseminated gonococcal infection. Ann Intern Med 1971;74;979–993.
17. DevinePA. Extraplevic manifestations of gonorrhea. Primary Care Update Obstet Gynecol 1998;5:233–237.
18. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: gonococcal infections. MMWR 2010;59(RR-12):49–56.
19. US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med 2005;3:263–267.
20. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332–336.
21. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates: United States 2000–2010. MMWR 2011;60:873–877.
22. CatesW Jr., WasserheitJN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771–1781.
23. WashingtonAE, JohnsonRE, SandersLL. Chlamydia trachomatis infections in the United States: what are they costing us? JAMA 1987;157:2070–2072.
24. GhysPD, FransenK, DialloMO, et al. The association between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS 1997;11:85–93.
25. GraystonJT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992;15:757–763.
26. KuoCC, ShorA, CampbellLA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841–849.
27. SchachterJ. Biology of Chlamydia trachomatis. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 391–405.
28. LyckeE, LowhagenG-B, HallagenG, et al. The risk of transmission of genital Chlamydia trachomatis infection is less frequent than that of Neisseria gonorrhoeae infection. Sex Trans Dis 1980;7:6–10.
29. StammWE. Chlamydia trachomatis infections of the adult. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 407–422.
30. MardhP-A. Is Europe ready for STD screening?Genitourin Med 1997;73:96–98.
31. KatzBP. Declining prevalence of chlamydial infection among adolescent girls. Sex Transm Dis 1996;23:226–229.
32. BatteigerBE, TuW, OfnerS, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010;201(Suppl 2):178.
33. OhMK, CloudCA, BakerSL, et al. Chlamydial infection and sexual behavior in young pregnant teenagers. Sex Transm Dis 1993;20:45–50.
34. SaltzGR. Chlamydia trachomatis cervical infections in female adolescents. J Pediatr 1981;98:981.
35. SchachterJ, StonerE, MoncodaJ. Screening for chlamydial infections in women attending Family Planning Clinics: evaluations of presumptive indicators for therapy. West J Med 1983;138:375–379.
36. SchachterJ. Chlamydia infections (3 parts). N Engl J Med 1978;298:428–435, 490–495, 540–549.
37. SweetRL, GibbsRS. Infectious Diseases of the Female Genital Tract, Ch. 3: Chlamydial infection. Philadelphia, PA: Lippincott Williams & Wilkins, 2009, pp. 18–40.
38. BrunhamR. Epidemiological and clinical correlates of C. trachomatis and N. gonorrhoeae infection among women attending an STD clinic. Clin Res 1981;29:47A.
39. StammWE, WagnerKF, AnselR, et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980;303:409–415.
40. WiesenfeldHC, HillierSL, KrohnMA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002;100:456–463.
41. CatesW Jr., RolfsRT, AralSO. Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update. Epidemiol Rev 1990;12:199–200.
42. SweetRL. Microbiologic etiology of acute pelvic inflammatory disease. In SweetRL, LandersDV (eds.) Pelvic Inflammatory Disease, Springer-Verlag, 1996, pp. 19–48.
43. MardhP-A, RipaKT, SvenssonL, et al. Chlamydia trachomatis in patients with acute salpingitis. N Engl J Med 1977;296:1377–1379.
44. PattonDL, MooreDE, SpadoniLR, et al. A comparison of the fallopian tube's response to overt and silent salpingitis. Obstet Gynecol 1989;73:622–630.
45. Muller-SchoopJW, WangS-P, MunzingerJ, et al. Chlamydia trachomatis as a possible cause of peritonitis and perihepatitis in young women. BMJ 1978;1:1022–1024.
46. MoneyDM, HawesSE, EschenbachDA, et al. Antibodies to the Chlamydia 60 kd heat-shock protein are associated with laparoscopically confirmed perihepatitis. Am J Obstet Gynecol 1997;176:870–877.
47. ThygesonP, MengertWF. The virus of inclusion conjunctivitis: further observations. Arch Ophthalmol 1936;15:377–410.
48. MordhorstCH, DawsonC. Sequelae of neonatal inclusion conjunctivitis and associated disease in parents. Am J Ophthalmol 1971;71:861–867.
49. WagerGP, MartinDH, KoutskyL, et al. Puerperal infectious morbidity: relationship to route of delivery and to antepartum Chlamydia trachomatis infection. Am J Obstet Gynecol 1980;138:1028–1033.
50. PlummerFA, LagaM, BrunhamRC, et al. Postpartum upper genital tract infections in Nairobi, Kenya. Epidemiology, etiology and risk factors. J Infect Dis 1987;156:92–97.
51. SweetRL, LandersDV, WalkerC, SchachterJ. Chlamydia trachomatis infection and pregnancy outcome. Am J Obstet Gynecol 1987;156:824–833.
52. MollerBR, AhronsS, LaurinJ, et al. Pelvic infection after elective abortion associated with Chlamydia trachomatis. Obstet Gynecol 1982;59:210–213.
53. Centers for Disease Control and Prevention. Guidelines for the Laboratory Diagnosis of Gonorrhea, Chlamydia and Syphilis. Atlanta, GA: Centers for Disease Control and Prevention, 2009.
54. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010: chlamydial infections. MMWR 2010;59:44–48.
55. SchachterJ, CherneskyMA, WillisDE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725–728.
56. DoshiJS, PowerJ, AllenE. Acceptibility of Chlamydia screening using self-taken vaginal swabs. Int J STD AIDS 2008;19:507–509.
57. US Preventive Services Task Force. Screening for Chlamydial Infection. Rockville, MD: US Preventive Services Task Force, 2007.
58. LauCY, QureshiAK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002;29:497–502.
59. CrombleholmeWR, SchachterJ, GrossmanM, LandersDV, SweetRL. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet Gynecol 1990;75:752–756.
60. Centers for Disease Control and Prevention. Primary and secondary syphilis: United States 1998. MMWR 1999;48:873–878.
61. Centers for Disease Control. Continuing increase in infectious syphilis: United States. MMWR 1988;37:35–38.
62. Centers for Disease Control and Prevention. Congenital syphilis: United States, 1998. MMWR 1999;48:757–761.
63. Centers for Disease Control and Prevention. Primary and secondary syphilis: United States 2000–2001. MMWR 2002;51:971.
64. AralSO, HolmesKK. Social and behavioral determinants of the epidemiology of STDs: industrialized and the developing countries. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 39–76.
65. Centers for Disease Control and Prevention. 2009 Sexually Transmitted Diseases Surveillance. Atlanta, GA: Centers for Disease Control and Prevention (http://www.cdc.gov/std/stats09/default.htm, accessed 26 February 2014).
66. Centers for Disease Control. Syphilis trends in the United States. MMWR 1981;31:441–444.
67. TramontEC. Syphilis in adults: from Christopher Columbus to Sir Alexander Fleming to AIDS. Clin Infect Dis 1995;21:1361–1371.
68. ChapelTA. The signs and symptoms of secondary syphilis. Sex Trans Dis 1980;7:161–164.
69. YoumansJB. Syphilis and other venereal diseases. Med Clin North Am 1964;48:571–824.
70. KollmanTR, DobsonS. Syphilis. In RemingtonJS, KleinJO (eds.) Infectious Diseases of the Fetus and Newborn Infant. Philadelphia, PA: Saunders, 2011, pp. 524–563.
71. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: syphilis. MMWR 2010;59(RR-12):26–38.
72. World Health Organization. Sexually Transmitted Diseases: Three Hundred and Thirty-Three Million New, Curable Cases in 1995 [Press Release WHO/64]. Geneva: World Health Organization, 1995.
73. FloodJM, SafrinSK, BolanGA, et al. Multistrain outbreak of chancroid in San Francisco, 1989–1991. J Infect Dis 1993;167:1106–1111.
74. RonaldAR, AlbrittonW. Chancroid and Haemophilus ducreyi. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999 pp. 515–523.
75. DicarloRP. Chancroid epidemiology in New Orleans men. J Infect Dis 1995;173:446–452.
76. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: chancroid. MMWR 2010;59(RR-12):19–20.
77. PlummerFA. Clinical and microbiologic studies of genital ulcers in Kenyan women. Sex Trans Dis 1985;12:193.
78. LockettAE. Serum-free media for the isolation of Haemophilus ducreyi. Lancet 1991;338:326.
79. OrleKA. Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum and herpex simplex virus types 1 and 2 from genital ulcers. J Clin Microbiol 1996;34:49–54.
80. PerinePL, StammWR. Lymphogranuloma venereum. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 423–432.
81. SchachterJ, SmithDE, DawsonCR, et al. Lymphogranuloma venereum. I. Comparison of the Frei test, complement fixation test and isolation of the agent. J Infect Dis 1969;120:372–375.
82. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: lymphogranuloma venereum. MMWR 2010;59(RR-12):26.
83. O'FarrellN. Donovanosis. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 525–531.
84. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: granuloma inguinale. MMWR 2010;59(RR-12):25–26.
85. HolmesKK, MardhP-A (eds.) International Perspectives on Neglected Sexually Transmitted Diseases. Washington, DC: Hemisphere Publishing, 1983, pp. 205–217.
86. IMS Health. National Disease and Therapeutic Index. Parsippany, NJ: IMS Health, 2013 (https://web01.imshealth.com/ndti/ndtilogin.aspx, accessed 26 February 2014).
87. Centers for Disease Control and Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years: United States, 2005–2008. MMWR 2010;59:626–629.
88. XuF, MarkowitzLE, GottliebSS, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in pregnant women in the United States. Am J Obstet Gynecol 2007;196:43.e1–43.e6.
89. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: genital HSV infection. MMWR 2010;59(RR-12):20–25.
90. TronsteinE, JohnstonC, HuangM-L, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic periods with HSV-2 infection. JAMA 2011;308:1441–1449.
91. BrownZA, SelkeS, ZehJ, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509–515.
92. ArvinAM, WhitleyRJ. Herpes simplex virus infection. In RemingtonJS, KleinJV (eds.) Infectious Diseases of the Fetus and Newborn Infant. Philadelphia, PA: Saunders, 2001, pp. 425–446.
93. SheffieldJS, HollierLM, HillJB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systemic review. Obstet Gynecol 2003;102:1396–1403.
94. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 82: management of herpes in pregnancy. Obstet Gynecol 2007;109:1489–1498.
95. CotchMF, PastorekJG III, NugentRP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and preterm study group. Sex Transm Dis 1997;24:353–360.
96. LagaM, ManokaA, KivuvuM, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95–102.
97. GardnerH, DukesCD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified “nonspecific” vaginitis. Am J Obstet Gynecol 1955;69:962.
98. SweetRL, GibbsRS. Infectious Diseases of the Female Genital Tract, Ch. 11: Infectious vulvovaginitis. Philadelphia, PA: Lippincott, Williams & Wilkins, 2009, pp. 96–206.
99. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: trichomoniasis. MMWR 2010;59(RR-12):58–60.
100. MillerWC, SwygardH, HobbsMM, et al. The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis 2005;32:593–598.
101. van der PolPB, WilliamsJA, OrrDP, et al. Prevalence, incidence, natural history and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192:2039–2044.
102. SuttonM, SternbergM, KoumansEH, et al. The prevalence of Trichomonas vaginalis infection among reproductive age women in the United States 2001–2004. Clin Infect Dis 2007;45:1319–1326.
103. AllsworthJE, RaftnerJA, PeipertJF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis 2009;36:738–744.
104. HardyPH, NellEE, SpenceMR, et al. Prevalence of six sexually transmitted disease agents among pregnant inner city adolescents and pregnancy outcome. Lancet 1984;8:333.
105. MasonPR, BrownI. Trichomonas in pregnancy. Lancet 1980;11:1025.
106. KlebanoffMA, CareyJC, HauthJC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487–493.
107. MullerM. LossickJG, GorrellTE, et al. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Trans Dis 1988;15:17.
108. Platts-MillsTAE, ReinMF. Scabies. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases, New York: McGraw-Hill, 1999, pp. 645–650.
109. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2010: scabies. MMWR 2010;59:89–90.
110. OrielJD. Ectoparasites. In HolmesKK, MardhP-A (eds.) International Perspectives on Neglected Sexually Transported Diseases. Washington, DC: Hemisphere Publishing, 1983, pp. 131–138.
111. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2010: pediculosis pubis. MMWR 2010;59(RR-12):88–89.
112. KwittenJ. Molluscum contagiosum: some new histologic observations. Mt Sinai J Med NY 1980;47:583–588.
113. BrownST, NalleyJF, KrausSJ. Molluscum contagiosum. Sex Transm Dis 1981;8:227–234.
114. KoutskyLA, KiviatNB. Genital human papillomavirus. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 347–359.
115. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 1995. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services, 1996.
116. Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press, 1997.
117. GallSA. Human papillomavirus infection. In MeddPD, HagerWD, FaroS (eds.) Protocols for Infectious Diseases in Obstetrics and Gynecology. Malden, MA: Blackwell Science, 2000, pp. 380–389.
118. InsingaRP, DasbachEJ, MyersER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397–1403.
119. KoutskyLA, GallowayDA, HolmesKK. Epidemiology of genital papillomavirus infection. Epidemiol Rev 1988;10:122–163.
120. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: cervical cancer screening for women who attend STD clinics or have a history of STDs. MMWR 2010;59(RR-12):70–78.
121. WinerRL, LeeS-K, HughesJP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218–226.
122. HalpertR, FruchterRG, SedlisA, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251–258.
123. GarryR, JonesR. Relationship between cervical condylomata, pregnancy and subclinical papillomavirus infection. J Reprod Med 1985;30:393–396.
124. WernessBA. Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression. In DeVitaJT (ed.) Important Advances in Oncology. Philadelphia, PA: Lippincott, 1991, p. 3.
125. BristowRE, MontzFJ. Human papillomavirus: molecular biology and screening applications in cervical neoplasia: a primer for primary care physicians. Prim Care Update Obstet Gynecol 1995;5:238–246.
126. BeutnerKR, WileyDJ, DouglasJM, et al. Genital warts and their treatment. Clin Infect Dis 1999;28(Suppl):S37–S56.
127. ChamberlainMJ, ReynoldsAL, YeomenWB. Toxic effects of podophyllin application in pregnancy. BMJ 1972;3:391–392.